A phase II trial including 17 patients with unresectable ACC, investigated the efficacy of dovitinib, a multi-kinase inhibitor with nonselective activity against the FGFR (targeting also colony-stimulating factor 1 receptor/CSF1R and VEGF) [79], reported only one partial response. The gene discussed is CSF1R; the disease is adrenal cortex carcinoma.